OnKure Therapeutics (OKUR) director receives 7,650 stock options grant

Rhea-AI Filing Summary

OnKure Therapeutics director Edward T. Mathers received a stock option grant representing 7,650 shares of Class A Common Stock. The option has an exercise price of $4.30 per share and expires on June 3, 2036. All 7,650 options will vest on the earlier of June 4, 2027 or the day before OnKure’s next annual meeting of stockholders, contingent on his continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mathers Edward T

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	7,650	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 7,650 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 7,650 options Exercise price: $4.30 per share Expiration date: June 3, 2036 +2 more

5 metrics

Options granted 7,650 options Stock Option grant to Edward T. Mathers

Exercise price $4.30 per share Exercise price for the stock options

Expiration date June 3, 2036 Option term end date

Underlying shares 7,650 shares Class A Common Stock underlying the options

Vesting date trigger June 4, 2027 or before next annual meeting 100% vesting condition, subject to continued service

Key Terms

Stock Option (right to buy), Class A Common Stock, exercise price, annual meeting of stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Class A Common Stock financial

"underlying_security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

exercise price financial

"conversion_or_exercise_price: 4.3000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders"

vesting financial

"100% of the shares subject to the option will vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/08/2026 - 06:33 PM Accepted by SEC EDGAR 06/08/2026 - 06:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mathers Edward T

(Last) (First) (Middle)

104 5TH AVE

19TH FLOOR

(Street)

NEW YORK NEW YORK 10011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.3	06/04/2026		A		7,650		(1)	06/03/2036	Class A Common Stock	7,650	$0	7,650	D

Explanation of Responses:

1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

	/s/ Zachary Bambach, attorney-in-fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did OnKure Therapeutics (OKUR) director Edward T. Mathers report on this Form 4?

Edward T. Mathers reported receiving a grant of stock options for 7,650 shares of OnKure Class A Common Stock. These options are compensation-related, not an open-market purchase or sale, and give him the right to buy shares at a fixed exercise price.

What are the key terms of Edward T. Mathers’ OnKure (OKUR) stock option grant?

The grant covers 7,650 stock options with an exercise price of $4.30 per share and an expiration date of June 3, 2036. Each option is tied to one share of OnKure’s Class A Common Stock as the underlying security.

When do Edward T. Mathers’ OnKure (OKUR) stock options vest?

One hundred percent of the 7,650 stock options will vest on the earlier of June 4, 2027, or the day prior to OnKure Therapeutics’ next annual meeting of stockholders, assuming Mathers continues as a service provider through that vesting date.

Is Edward T. Mathers buying or selling OnKure (OKUR) shares in this filing?

This filing shows a grant of stock options as compensation, not a market trade. The transaction is coded as an acquisition (grant/award) of derivative securities, giving him rights to purchase shares in the future at $4.30 per share.

How many OnKure (OKUR) options does Edward T. Mathers hold after this grant?

After the transaction, Mathers holds 7,650 stock options directly, according to the Form 4. Each option is exercisable for one share of OnKure Class A Common Stock, subject to the vesting conditions and the June 3, 2036 expiration date.